Vaccine development creating immunity — hepatitis C virus envelope protein E2 (HCV E2) emerging as vaccine antigen target enabling development of prophylactic HCV vaccines preventing viral infection through elicited neutralizing antibody responses and T-cell immunity, establishing HCV vaccination as therapeutic opportunity addressing HCV infection burden affecting approximately 71 million...